The AVERROES double-blinded , randomized trial demonstrated that apixaban reduces the risk of stroke or systemic embolism ( SSE ) by 55 % compared with aspirin without an increase in major bleeding in patients with atrial fibrillation either who previously tried but failed vitamin K antagonists ( VKA ) therapy or who were expected to be unsuitable for VKA therapy .